Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.50 |
| ▸ | HTR1A | P08908 | 5/20 | 0.50 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089874 | 0.91 | KDM2B (0.55) | MEN1KMT2ADRD2HTR1AHSD17B10 | |
| SCHEMBL23097718 | 0.85 | DRD2 (0.68) | DRD2HTR1AHTR2ADRD3TMEM97 | |
| SCHEMBL13103801 | 0.83 | DRD2 (0.56) | DRD2HTR1AHTR2ADRD3TMEM97 | |
| SCHEMBL25839407 | 0.82 | SLC6A2 (0.50) | MEN1KMT2ADRD2HTR1AHTR2A | |
| SCHEMBL19297522 | 0.82 | SLC6A2 (0.60) | DRD2HTR1AHTR2ADRD3TMEM97 | |
| SCHEMBL29314713 | 0.81 | SIGMAR1 (0.71) | DRD2HTR1AHTR2ADRD3TMEM97 | |
| SCHEMBL20231608 | 0.81 | DRD2 (0.51) | MEN1KMT2ADRD2HTR1AHTR2A | |
| SCHEMBL13436345 | 0.80 | HRH3 (0.41) | MEN1KMT2ADRD2HTR1AHTR2A | |
| SCHEMBL12278862 | 0.78 | ALDH1A1 (0.58) | MEN1KMT2ADRD2HTR1AHTR2A | |
| SCHEMBL24478533 | 0.78 | HSD17B10 (0.51) | KMT2ADRD2HTR1ASIGMAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | MEN1 4006/4885KMT2A 2231/4885DRD2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.